Congestive Heart Failure (CHF) Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies – Novartis, Amgen, Otsuka, Mesoblast, Cytokinetics, Tenax, BioCardia, Bayer, Merck 1
Congestive Heart Failure (CHF) Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Novartis, Amgen, Otsuka, Mesoblast, Cytokinetics, Tenax, BioCardia, Bayer, Merck
Delveinsight Business Research LLP
As per DelveInsight, the Congestive Heart Failure market is expected to witness significant growth in the coming years owing to the rising prevalence of heart failure cases due to the rapidly aging population and growing awareness among people, market penetration in CHF due to label expansion, and entry of new emerging therapies.

DelveInsight’s “Congestive Heart Failure (CHF) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congestive Heart Failure market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Congestive Heart Failure market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Congestive Heart Failure Market

Congestive Heart Failure (CHF): An Overview

Heart Failure (HF), often referred to as Congestive heart failure (CHF), is a serious condition, and usually, there’s no cure. But many people with heart failure lead a full, enjoyable life when the condition is managed with heart failure medications and healthy lifestyle changes.

Patients with heart failure can present with a challenging array of comorbid medical conditions. GPs have an important role in recognizing and managing these to ensure that heart failure therapies are not compromised and that only necessary medications are prescribed.

Congestive Heart Failure (CHF) Market Key Facts

  • The Congestive Heart Failure market size in the seven major markets was found to be USD 7,412 million in 2021, which is expected to grow by 2032.

  • The United States accounts for the largest market size of Congestive Heart Failure compared to EU5 (Germany, the United Kingdom, Italy, France, and Spain) and Japan.

  • In the United States, the market size of CHF is anticipated to rise from USD 4,484 million in 2021.

  • Among the EU5 countries, Germany had the largest market size in 2021, while the UK had the smallest.

  • The total prevalent cases of Heart Failure in 2021 in the 7MM were estimated to be 16,630,500+.

  • Estimates show that the highest cases of Congestive Heart Failure in the 7MM were in the United States, followed by JapanGermanythe United KingdomItalyFrance, and Spain in the year 2021.

Congestive Heart Failure (CHF) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Congestive Heart Failure market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Congestive Heart Failure market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Congestive Heart Failure (CHF) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Congestive Heart Failure (CHF) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congestive Heart Failure market or expected to get launched during the study period. The analysis covers the Congestive Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congestive Heart Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Congestive Heart Failure Market Will Evolve by 2032 @

Congestive Heart Failure (CHF) Therapeutics Analysis

Currently, the treatment regimen for heart failure involves the use of ACE inhibitors, Angiotensin II receptor blockers (ARBs), Mineralocorticoid receptor antagonists (MRAs)If-Channel Inhibitor, Beta-blockers, ARNIs, diuretics, digitalis, dinitrate and many others, which are prescribed as either monotherapy or in most cases as a combination with each other. Several major pharma and biotech giants are actively working in the Congestive Heart Failure Therapeutics market to improve the treatment scenario. 

 Some of the key companies in the Congestive Heart Failure (CHF) Therapeutics Market include:

  • Novartis

  • Boehringer Ingelheim and Eli Lilly

  • Bayer and Merck

  • AstraZeneca

  • Amgen

  • Otsuka Pharmaceutical

  • Cytokinetics

  • Mesoblast

  • Novo Nordisk

  • Lexicon Pharmaceuticals

  • scPharmaceuticals

  • Bristol-Myers Squibb

  • Intra-Cellular Therapies

  • Tenax Therapeutics

  • BioCardia

And many others

 Congestive Heart Failure (CHF) Therapies covered in the report include:

  • Entresto (Novartis)

  • Jardiance (Boehringer Ingelheim and Eli Lilly)

  • Verquvo (Bayer and Merck)

  • Farxiga (AstraZeneca)

  • Corlanor (Amgen)

  • CHF Emerging Drugs

  • OPC-61815 (Otsuka Pharmaceutical)

  • Omecamtiv Mecarbil (Cytokinetics)

  • Rexlemestrocel-L (Mesoblast)

  • Finerenone (Bayer)

  • Semaglutide (Novo Nordisk)

  • AZD4831 (AstraZeneca)

  • Lenrispodun (ITI – 214) (Intra-Cellular Therapies)

  • Sotagliflozin (Lexicon Pharmaceuticals)

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Congestive Heart Failure Competitive Intelligence Analysis

4. Congestive Heart Failure Market Overview at a Glance

5. Congestive Heart Failure Disease Background and Overview

6. Congestive Heart Failure Patient Journey

7. Congestive Heart Failure Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Congestive Heart Failure Treatment Algorithm, Current Treatment, and Medical Practices

9. Congestive Heart Failure Unmet Needs

10. Key Endpoints of Congestive Heart Failure Treatment

11. Congestive Heart Failure Marketed Products

12. Congestive Heart Failure Emerging Drugs and Latest Therapeutic Advances

13. Congestive Heart Failure Seven Major Market Analysis

14. Attribute Analysis

15. Congestive Heart Failure Market Outlook (In US, EU5, and Japan)

16. Congestive Heart Failure Access and Reimbursement Overview

17. KOL Views on the Congestive Heart Failure Market

18. Congestive Heart Failure Market Drivers

19. Congestive Heart Failure Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Familial Hypercholesterolemia Market

“Familial Hypercholesterolemia Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Familial Hypercholesterolemia Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Leave a Reply

Your email address will not be published. Required fields are marked *